OBJECTIVE: Mounting evidence indicates that alterations in AKT proteins play an important role in the pathogenesis of cancer. The objective of this study was to see whether common human carcinomas harbor AKT mutations that might contribute to the development of cancer. METHODS: We performed mutational analysis of the kinase domains of AKT1-AKT3 by a single-strand conformation polymorphism assay in 294 carcinoma tissues from the stomach, lung, colon and breast. RESULTS: Overall, we detected three somatic mutations in AKT2, but no mutations in AKT1 or AKT3 in the 294 cancer tissues. The AKT2 mutations were detected in 1 of 51 gastric carcinomas (2.0%) and 2 of 79 lung carcinomas (2.5%). AKT2 mutations consisted of one missense mutation and 2 splice site mutations in the intron. We simultaneously analyzed somatic mutations in EGFR, ERBB2, K-RAS, PIK3CA and BRAF genes in the 3 samples with the AKT2 mutations, and found a lung adenocarcinoma with the AKT2 missense mutation harbored an EGFR mutation. CONCLUSION: This study demonstrated that somatic mutations in the kinase domain of AKT2 occur in a small fraction of common human cancers, and suggested that alterations in the AKT2-mediated signaling pathway by AKT2 mutation could contribute to the development of some cases of human cancers. Copyright (c) 2006 S. Karger AG, Basel.
OBJECTIVE: Mounting evidence indicates that alterations in AKT proteins play an important role in the pathogenesis of cancer. The objective of this study was to see whether common humancarcinomas harbor AKT mutations that might contribute to the development of cancer. METHODS: We performed mutational analysis of the kinase domains of AKT1-AKT3 by a single-strand conformation polymorphism assay in 294 carcinoma tissues from the stomach, lung, colon and breast. RESULTS: Overall, we detected three somatic mutations in AKT2, but no mutations in AKT1 or AKT3 in the 294 cancer tissues. The AKT2 mutations were detected in 1 of 51 gastric carcinomas (2.0%) and 2 of 79 lung carcinomas (2.5%). AKT2 mutations consisted of one missense mutation and 2 splice site mutations in the intron. We simultaneously analyzed somatic mutations in EGFR, ERBB2, K-RAS, PIK3CA and BRAF genes in the 3 samples with the AKT2 mutations, and found a lung adenocarcinoma with the AKT2 missense mutation harbored an EGFR mutation. CONCLUSION: This study demonstrated that somatic mutations in the kinase domain of AKT2 occur in a small fraction of common humancancers, and suggested that alterations in the AKT2-mediated signaling pathway by AKT2 mutation could contribute to the development of some cases of humancancers. Copyright (c) 2006 S. Karger AG, Basel.
Authors: Ramesh K Ramanathan; Shannon L McDonough; Hagen F Kennecke; Syma Iqbal; Joaquina C Baranda; Tara E Seery; Howard J Lim; Aram F Hezel; Gina M Vaccaro; Charles D Blanke Journal: Cancer Date: 2015-03-30 Impact factor: 6.860
Authors: Y Liao; Y Wei; X Zhou; J-Y Yang; C Dai; Y-J Chen; N K Agarwal; D Sarbassov; D Shi; D Yu; M-C Hung Journal: Oncogene Date: 2009-05-18 Impact factor: 9.867
Authors: Long P Le; Dora Dias-Santagata; Amanda C Pawlak; Arjola K Cosper; Anh Thu Nguyen; M Angelica Selim; April Deng; Nora K Horick; A John Iafrate; Martin C Mihm; Mai P Hoang Journal: PLoS One Date: 2012-10-09 Impact factor: 3.240
Authors: Joanna D Holbrook; Joel S Parker; Kathleen T Gallagher; Wendy S Halsey; Ashley M Hughes; Victor J Weigman; Peter F Lebowitz; Rakesh Kumar Journal: J Transl Med Date: 2011-07-25 Impact factor: 5.531